Neyts, Johan,
Towards the development of potent therapy against the Hepatitis C virus [electronic resource] / Johan Neyts. - London : Henry Stewart Talks, 2011. - 1 online resource (1 streaming video file (50 min.) : color, sound). - Antivirals : latest developments and future progress, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Antivirals. .
Animated audio-visual presentation with synchronized narration. Title from title frames.
Contents: The HCV genome and replication cycle -- Interferon development -- Ribavirin -- Antiviral and GTP depletion correlation -- Selective inhibitors of HCV replication -- The NS2 cysteine and the NS3 serine proteases -- Protease inhibitors -- The NS3 helicase as an antiviral target -- NS4A/NS3, NS4B and NS5A as antiviral targets -- The NS5B RNA dependent RNA polymerase -- Nucleoside and non-nucleoside HCV inhibitors -- Double and triple combination therapies -- Debio-025 -- Resistance to HCV inhibitors -- D320E peptide mutation effect -- Role of NS5A or NS5B in resistance -- Wild type and CypA knock down studies -- Cis-trans isomerase activity of cyclophilins.
Access restricted to subscribers.
Mode of access: World Wide Web.
2974 Henry Stewart Talks
Antiviral agents.
Hepatitis C virus.
Hepatitis C--Treatment.
Antiviral Agents.
Hepacivirus.
Hepatitis C--drug therapy.
Towards the development of potent therapy against the Hepatitis C virus [electronic resource] / Johan Neyts. - London : Henry Stewart Talks, 2011. - 1 online resource (1 streaming video file (50 min.) : color, sound). - Antivirals : latest developments and future progress, 2056-452X . - Henry Stewart talks. Biomedical & life sciences collection. Antivirals. .
Animated audio-visual presentation with synchronized narration. Title from title frames.
Contents: The HCV genome and replication cycle -- Interferon development -- Ribavirin -- Antiviral and GTP depletion correlation -- Selective inhibitors of HCV replication -- The NS2 cysteine and the NS3 serine proteases -- Protease inhibitors -- The NS3 helicase as an antiviral target -- NS4A/NS3, NS4B and NS5A as antiviral targets -- The NS5B RNA dependent RNA polymerase -- Nucleoside and non-nucleoside HCV inhibitors -- Double and triple combination therapies -- Debio-025 -- Resistance to HCV inhibitors -- D320E peptide mutation effect -- Role of NS5A or NS5B in resistance -- Wild type and CypA knock down studies -- Cis-trans isomerase activity of cyclophilins.
Access restricted to subscribers.
Mode of access: World Wide Web.
2974 Henry Stewart Talks
Antiviral agents.
Hepatitis C virus.
Hepatitis C--Treatment.
Antiviral Agents.
Hepacivirus.
Hepatitis C--drug therapy.